35151213|t|Esculentoside A alleviates cognitive deficits and amyloid pathology through peroxisome proliferator-activated receptor gamma-dependent mechanism in an Alzheimer's disease model.
35151213|a|BACKGROUND: Alzheimer's disease (AD) is characterized clinically by cognitive deficits and pathologically by amyloid-beta (Abeta) deposition and tau aggregation, as well as the brain atrophy. Esculentoside A (EsA), a neuroprotective saponin, is isolated from Phytolacca esculenta and shows potent health-promoting effects in a variety of experimental models. However, there are minimal reports on the effects of EsA on triple transgenic AD mice. PURPOSE: The current research aimed at investigating the protective effects and underlying mechanisms of EsA on the mitigation of cognitive deficits and pathology in triple transgenic AD mice. METHODS: Triple transgenic AD mice (3 x Tg-AD) of 8 months old received intraperitoneal treatment of 5 or 10 mg/kg EsA for 8 consecutive weeks. Morris water maze test and open field test were made to evaluate the cognitive function and degree of anxiety of the mice. Liquid chromatography with tandem mass spectrometry analysis was performed to characterize and to quantify EsA in the blood and brain of mice. Immunofluorescence assay and Western blot were adopted to measure the levels of peroxisome proliferator-activated receptor gamma (PPARgamma) and key proteins in Abeta pathology, ER stress- and apoptosis-associated pathways. The combination of EsA with PPARgamma were theoretically calculated by molecular docking programs and experimentally confirmed by the bio-layer interferometry technology. RESULTS: Supplemental EsA could improve the cognitive deficits of 3 x Tg-AD mice. EsA penetrated the brain-blood barrier to exert a strong effect on AD mice, evidenced as decreasing Abeta generation, reducing the degrees of oxidative and ER stress, and mitigating neuronal apoptosis through the increase of PPARgamma expression. In the culture of primary neurons, addition of PPARgamma inhibitor GW9662 eliminated the effects of EsA on AD pathologies. Direct combination of EsA with PPARgamma were demonstrated by molecular docking programs and bio-layer interferometry technology. CONCLUSIONS: For the first time, these outcomes revealed that EsA could penetrate the brain-blood barrier to exert a strong effect on ameliorating cognitive deficits in 3 x Tg-AD mice and exert neuroprotective effects toward AD pathology via PPARgamma-dependent mechanism.
35151213	0	15	Esculentoside A	Chemical	MESH:C076297
35151213	27	45	cognitive deficits	Disease	MESH:D003072
35151213	50	67	amyloid pathology	Disease	MESH:C000718787
35151213	76	124	peroxisome proliferator-activated receptor gamma	Gene	19016
35151213	151	170	Alzheimer's disease	Disease	MESH:D000544
35151213	190	209	Alzheimer's disease	Disease	MESH:D000544
35151213	211	213	AD	Disease	MESH:D000544
35151213	246	264	cognitive deficits	Disease	MESH:D003072
35151213	301	306	Abeta	Gene	11820
35151213	355	368	brain atrophy	Disease	MESH:C566985
35151213	370	385	Esculentoside A	Chemical	MESH:C076297
35151213	387	390	EsA	Chemical	MESH:C076297
35151213	411	418	saponin	Chemical	MESH:D012503
35151213	437	457	Phytolacca esculenta	Species	3528
35151213	590	593	EsA	Chemical	MESH:C076297
35151213	615	617	AD	Disease	MESH:D000544
35151213	618	622	mice	Species	10090
35151213	729	732	EsA	Chemical	MESH:C076297
35151213	754	772	cognitive deficits	Disease	MESH:D003072
35151213	808	810	AD	Disease	MESH:D000544
35151213	811	815	mice	Species	10090
35151213	844	846	AD	Disease	MESH:D000544
35151213	847	851	mice	Species	10090
35151213	860	862	AD	Disease	MESH:D000544
35151213	932	935	EsA	Chemical	MESH:C076297
35151213	1063	1070	anxiety	Disease	MESH:D001007
35151213	1078	1082	mice	Species	10090
35151213	1191	1194	EsA	Chemical	MESH:C076297
35151213	1221	1225	mice	Species	10090
35151213	1307	1355	peroxisome proliferator-activated receptor gamma	Gene	19016
35151213	1357	1366	PPARgamma	Gene	19016
35151213	1388	1393	Abeta	Gene	11820
35151213	1470	1473	EsA	Chemical	MESH:C076297
35151213	1479	1488	PPARgamma	Gene	19016
35151213	1644	1647	EsA	Chemical	MESH:C076297
35151213	1666	1684	cognitive deficits	Disease	MESH:D003072
35151213	1695	1697	AD	Disease	MESH:D000544
35151213	1698	1702	mice	Species	10090
35151213	1704	1707	EsA	Chemical	MESH:C076297
35151213	1771	1773	AD	Disease	MESH:D000544
35151213	1774	1778	mice	Species	10090
35151213	1804	1809	Abeta	Gene	11820
35151213	1886	1904	neuronal apoptosis	Disease	MESH:D065703
35151213	1929	1938	PPARgamma	Gene	19016
35151213	1998	2007	PPARgamma	Gene	19016
35151213	2018	2024	GW9662	Chemical	MESH:C457499
35151213	2051	2054	EsA	Chemical	MESH:C076297
35151213	2058	2060	AD	Disease	MESH:D000544
35151213	2096	2099	EsA	Chemical	MESH:C076297
35151213	2105	2114	PPARgamma	Gene	19016
35151213	2266	2269	EsA	Chemical	MESH:C076297
35151213	2351	2369	cognitive deficits	Disease	MESH:D003072
35151213	2380	2382	AD	Disease	MESH:D000544
35151213	2383	2387	mice	Species	10090
35151213	2429	2431	AD	Disease	MESH:D000544
35151213	2446	2455	PPARgamma	Gene	19016
35151213	Positive_Correlation	MESH:D065703	19016
35151213	Negative_Correlation	MESH:C076297	MESH:D065703
35151213	Negative_Correlation	MESH:C076297	MESH:D003072
35151213	Negative_Correlation	MESH:C076297	11820
35151213	Negative_Correlation	MESH:C457499	19016
35151213	Positive_Correlation	MESH:C076297	MESH:D001007
35151213	Positive_Correlation	MESH:C076297	19016
35151213	Negative_Correlation	MESH:C076297	MESH:C457499
35151213	Association	MESH:D000544	19016
35151213	Negative_Correlation	MESH:C076297	MESH:C000718787
35151213	Association	MESH:D003072	19016
35151213	Association	MESH:D000544	11820
35151213	Negative_Correlation	MESH:C076297	MESH:D000544

